FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281691282> ?p ?o ?g. }

• W4281691282 endingPage "542" @default.
• W4281691282 startingPage "533" @default.
• W4281691282 abstract "To evaluate the efficacy and safety of intravenous immunoglobulin (IVIG) in the treatment of dermatomyositis (DM) and polymyositis (PM).We searched PubMed, Embase, and the China National Knowledge Infrastructure for relevant studies from July 1919 to May 2021.Seventeen papers pertinent to our questions were found: In a meta-analysis, we found that IVIG significantly improved the level of CK (SMD (STD. Mean Difference) = -0.69; 95%CI -0.93, -0.46; P < 0.0001), Manual Muscle Test (SMD = 1.12; 95%CI 0.77, 1.47; P < 0.00001), Medical Research Council (SMD = 1.59; 95%CI 0.86, 2.33; P < 0.00001), Activities of Daily Living (SMD = 1.07; 95%CI 0.59, 1.56; P < 0.0001). The CK levels in DM and PM were also significantly improved after IVIG (SMD = -0.73; 95%CI -1.12, -0.34; P = 0.0002 and SMD = -3.29; 95%CI -5.82, -0.76; P < 0.0001, respectively). The meta-analysis of three RCTs showed that there was a statistically significant improvement after IVIG (SMD = 0.63; 95%CI 0.22, 1.03; P = 0.002). In a random effects model, pooled muscle power improvement rate was 77% (95% CI: 66.0-87.0%). Meta-analyses of IVIG as first-line therapy showed a significant improvement of the CK level (SMD = -0.71; 95%CI -1.12, -0.30; P = 0.0007). The polled improvement rate of oesophageal disorders was 88% (95% CI: 80.0-95.0%). There was no statistically significant difference in the rate of improvement between the number of courses <2 and ≥2 (0.80% vs. 0.80%, P = 0.9). The proportion of corticosteroid-sparing success reached 81.8%. Adverse reactions following IVIG administration are usually mild and transient. Seven patients developed serious adverse events.IVIG seems to be an effective drug for DM/PM, improving muscle strength, CK levels, and oesophageal involvement, and it is well tolerated by patients." @default.
• W4281691282 created "2022-06-13" @default.
• W4281691282 creator A5005872065 @default.
• W4281691282 creator A5006537956 @default.
• W4281691282 creator A5021927954 @default.
• W4281691282 creator A5025476789 @default.
• W4281691282 creator A5035840776 @default.
• W4281691282 creator A5042700901 @default.
• W4281691282 creator A5064599095 @default.
• W4281691282 creator A5065592637 @default.
• W4281691282 creator A5067095480 @default.
• W4281691282 creator A5072088509 @default.
• W4281691282 creator A5074753488 @default.
• W4281691282 creator A5078020955 @default.
• W4281691282 creator A5083585731 @default.
• W4281691282 creator A5086556992 @default.
• W4281691282 creator A5090948350 @default.
• W4281691282 date "2022-06-04" @default.
• W4281691282 modified "2023-09-24" @default.
• W4281691282 title "The therapeutic efficacy and safety of intravenous immunoglobulin in dermatomyositis and polymyositis: A systematic review and meta-analysis" @default.
• W4281691282 cites W1563183497 @default.
• W4281691282 cites W1971648636 @default.
• W4281691282 cites W1975347539 @default.
• W4281691282 cites W1976535033 @default.
• W4281691282 cites W1988867500 @default.
• W4281691282 cites W1992854450 @default.
• W4281691282 cites W2000677082 @default.
• W4281691282 cites W2002779814 @default.
• W4281691282 cites W2013362643 @default.
• W4281691282 cites W2017651908 @default.
• W4281691282 cites W2022364775 @default.
• W4281691282 cites W2030385924 @default.
• W4281691282 cites W2070113718 @default.
• W4281691282 cites W2071218913 @default.
• W4281691282 cites W2071489757 @default.
• W4281691282 cites W2073994360 @default.
• W4281691282 cites W2075372165 @default.
• W4281691282 cites W2087511707 @default.
• W4281691282 cites W2088802548 @default.
• W4281691282 cites W2135011891 @default.
• W4281691282 cites W2153688784 @default.
• W4281691282 cites W2165303288 @default.
• W4281691282 cites W2315610003 @default.
• W4281691282 cites W2575412201 @default.
• W4281691282 cites W2904523111 @default.
• W4281691282 cites W3149772139 @default.
• W4281691282 cites W4234853960 @default.
• W4281691282 cites W4288066268 @default.
• W4281691282 doi "https://doi.org/10.1093/mr/roac057" @default.
• W4281691282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35660927" @default.
• W4281691282 hasPublicationYear "2022" @default.
• W4281691282 type Work @default.
• W4281691282 citedByCount "3" @default.
• W4281691282 countsByYear W42816912822022 @default.
• W4281691282 countsByYear W42816912822023 @default.
• W4281691282 crossrefType "journal-article" @default.
• W4281691282 hasAuthorship W4281691282A5005872065 @default.
• W4281691282 hasAuthorship W4281691282A5006537956 @default.
• W4281691282 hasAuthorship W4281691282A5021927954 @default.
• W4281691282 hasAuthorship W4281691282A5025476789 @default.
• W4281691282 hasAuthorship W4281691282A5035840776 @default.
• W4281691282 hasAuthorship W4281691282A5042700901 @default.
• W4281691282 hasAuthorship W4281691282A5064599095 @default.
• W4281691282 hasAuthorship W4281691282A5065592637 @default.
• W4281691282 hasAuthorship W4281691282A5067095480 @default.
• W4281691282 hasAuthorship W4281691282A5072088509 @default.
• W4281691282 hasAuthorship W4281691282A5074753488 @default.
• W4281691282 hasAuthorship W4281691282A5078020955 @default.
• W4281691282 hasAuthorship W4281691282A5083585731 @default.
• W4281691282 hasAuthorship W4281691282A5086556992 @default.
• W4281691282 hasAuthorship W4281691282A5090948350 @default.
• W4281691282 hasConcept C126322002 @default.
• W4281691282 hasConcept C198451711 @default.
• W4281691282 hasConcept C2778751314 @default.
• W4281691282 hasConcept C2779387793 @default.
• W4281691282 hasConcept C28804328 @default.
• W4281691282 hasConcept C71924100 @default.
• W4281691282 hasConcept C90924648 @default.
• W4281691282 hasConcept C95190672 @default.
• W4281691282 hasConceptScore W4281691282C126322002 @default.
• W4281691282 hasConceptScore W4281691282C198451711 @default.
• W4281691282 hasConceptScore W4281691282C2778751314 @default.
• W4281691282 hasConceptScore W4281691282C2779387793 @default.
• W4281691282 hasConceptScore W4281691282C28804328 @default.
• W4281691282 hasConceptScore W4281691282C71924100 @default.
• W4281691282 hasConceptScore W4281691282C90924648 @default.
• W4281691282 hasConceptScore W4281691282C95190672 @default.
• W4281691282 hasIssue "3" @default.
• W4281691282 hasLocation W42816912821 @default.
• W4281691282 hasLocation W42816912822 @default.
• W4281691282 hasOpenAccess W4281691282 @default.
• W4281691282 hasPrimaryLocation W42816912821 @default.
• W4281691282 hasRelatedWork W149105571 @default.
• W4281691282 hasRelatedWork W2001944153 @default.
• W4281691282 hasRelatedWork W2047988042 @default.
• W4281691282 hasRelatedWork W2080077828 @default.
• W4281691282 hasRelatedWork W2081586044 @default.
• W4281691282 hasRelatedWork W2315269436 @default.

• next